-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Biomedical Engineering
- Cardiology
- Clinical Trials
- Clinics
- Consumer Products
- Counterfeit Products
- Critical Care Medicine
- Dentistry
- Dermatology
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA 2013
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Home Care
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Nephrology
- Neurology
- Nursing
- OBGYN
- Oncology
- Ophthalmology
- Orthopaedic Surgery
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Physical Medicine
- Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Risk Manager
- Surgery
- Uncategorized
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
Monthly Archives: August 2011
Celexa citalopram hydrobromide
Translation Celexa (citalopram hydrobromide): Drug Safety Communication – Abnormal Heart Rhythms Associated With High Doses AUDIENCE: Psychiatry, Cardiology ISSUE: FDA notified healthcare professionals and patients that the antidepressant Celexa (citalopram hydrobromide) should no longer be used at doses greater … Continue reading
Posted in FDA 2011, FDA Notice, Psychiatry
Tagged Abnormal Heart Rhythms, Cardiology, Celexa citalopram hydrobromide, dosage, drug risks, FDA notice, FDA warning, Psychiatry, safety label changes
Comments Off
Vasopressin Injection USP Multiple Dose Vials Recall
TranslationVasopressin Injection USP, Multiple Dose Vials: Recall – Sub-Potency AUDIENCE: Risk Manager, Pharmacy ISSUE: American Regent, Inc. is conducting a nationwide voluntary recall of multiple lots of Vasopressin Injection, USP to the Retail/Hospital level. This product recall was initiated by … Continue reading
Posted in FDA 2011, FDA Recall, Pharmacy, Risk Manager
Tagged FDA notice, FDA recall, Pharmacy, Recall, Risk Manager, Vasopressin Injection USP Multiple Dose Vials
Comments Off
Diflucan (fluconazole) Birth Defects
TranslationDiflucan (fluconazole): Drug Safety Communication – Long-term, High-dose Use During Pregnancy May Be Associated With Birth Defects AUDIENCE: OBGYN, Pharmacy, Infectious Disease ISSUE: FDA is informing the public that treatment with chronic, high doses (400-800mg/day) of Diflucan (fluconazole) during the … Continue reading
Posted in FDA 2011, FDA Notice, FDA Warning, OBGYN, Pharmacy
Tagged Birth Defects, Diflucan, FDA notice, FDA warning, Fluconazole, Infectious Disease, OBGYN, Pharmacy
Comments Off